



Arlington Scientific, Inc. Expands Leadership in Infectious Disease Diagnostics With Strategic ELISA Acquisition

Springville, Utah — February 12, 2026

Arlington Scientific, Inc. (ASI), a U.S.-based leader in infectious disease diagnostics with over 40 years of regulated manufacturing experience, today announced the completion of its acquisition of the EIA/ELISA product line from Awareness Technology, Inc. (Quest International / ReQuest® brand).

The acquired assays will be unified by **Arlington Scientific** under the **SeraQuest™** line, strengthening ASI's FDA-registered serology platform across agglutination, latex, and ELISA methodologies.

“As part of ASI's growth strategy, we focus on expanding in ways that reinforce our core strengths in manufacturing, quality, and regulatory execution. Bringing these established ELISA assays into ASI allows us to broaden our diagnostics offering and add the consistency and reliability our laboratory partners expect,” said Park Roney, President and Chief Executive Officer of Arlington Scientific.

About Arlington Scientific, Inc.

Arlington Scientific, Inc. (ASI) is a U.S.-based global medical technology company that develops, manufactures, and distributes in vitro diagnostic tests, automated diagnostic systems, and specialty medical devices for clinical laboratories worldwide. ASI manufactures more than **30 million RPR tests annually**, serves over **1,200 laboratories globally**, and developed the **ASI Evolution® platform**, the leading automated non-treponemal (RPR) syphilis analyzer FDA-cleared for diagnostic use, blood donor screening, and cadaveric donor screening.

ASI is advancing infectious disease diagnostics through disciplined innovation, manufacturing excellence, and rigorous regulatory execution—delivering reliable, high-performance solutions laboratories depend on.

For more information, visit www.arlingtonscientific.com.

